Scholarlink

Background <p>Non-alcoholic fatty liver disease (NAFLD) and type 2 Diabetes Mellitus are the major causes of significant mortality and morbidity. NAFLD and type 2 diabetes have common risk factors. SGLT-2 inhibitors are believed to have a beneficial effect on liver fat in patients with NAFLD and type 2 diabetes. However, there are limited data available on this aspect of empagliflozin use. Thus, we aimed to compare the impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD.</p> Methods <p>A comprehensive search of databases like PubMed, Google Scholar, and Cochrane Library was done. In the end, a detailed analysis was performed on a total of 6 finalized studies, all of which were randomized controlled trials. This comprehensive analysis consisted of a cohort of 589 Individuals.</p> Results <p>A total of six studies were included. Primary outcomes assessed were MRI-PDFF, AST, ALT, HOMA-IR and total bilirubin. Empagliflozin significantly reduced liver fat compared to placebo, with a pooled standardized mean difference (SMD) of −0.43 (95% CI: −0.82 to −0.04; <i>p</i> = 0.03; I² = 0%). AST also showed a significant reduction (SMD = −0.41; 95% CI: −0.66 to −0.16; <i>p</i> = 0.001; I² = 34%), while ALT showed a non-significant trend favoring empagliflozin (SMD = −0.60; 95% CI: −1.25 to 0.04; <i>p</i> = 0.07) with high heterogeneity (I² = 91%). No significant effects were observed for HOMA-IR (SMD = −0.10; 95% CI: −0.43 to 0.24; <i>p</i> = 0.57) or total bilirubin (SMD = −0.04; 95% CI: −1.16 to 1.08; <i>p</i> = 0.94). Among secondary outcomes, only liver segment VIII showed a significant benefit (SMD = −0.97; 95% CI: −1.68 to −0.25; <i>p</i> = 0.008), though heterogeneity remained substantial (I² = 79%). No significant changes were found in total cholesterol.</p> Conclusion <p>MRI-PDFF showed that empagliflozin significantly reduced liver fat and AST levels, indicating a beneficial effect on liver health in patients with type 2 diabetes and NAFLD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD: A systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2026年1月24日

查看全文
  • Muhammad Umais,
  • Hooriah Imtiaz,
  • Muhammad Luqman,
  • Sidra Anwar,
  • Muhammad Umer Iftikhar,
  • Kanwal Maheshwari,
  • Zarine Tasnim Sara,
  • Noor ul Huda Naseem,
  • Firose Afra Ibnath,
  • Abdul Rehman Shah Syed,
  • Muhammad Ali Muzammil

摘要

Background

Non-alcoholic fatty liver disease (NAFLD) and type 2 Diabetes Mellitus are the major causes of significant mortality and morbidity. NAFLD and type 2 diabetes have common risk factors. SGLT-2 inhibitors are believed to have a beneficial effect on liver fat in patients with NAFLD and type 2 diabetes. However, there are limited data available on this aspect of empagliflozin use. Thus, we aimed to compare the impact of empagliflozin on liver fat reduction in type 2 diabetes and NAFLD.

Methods

A comprehensive search of databases like PubMed, Google Scholar, and Cochrane Library was done. In the end, a detailed analysis was performed on a total of 6 finalized studies, all of which were randomized controlled trials. This comprehensive analysis consisted of a cohort of 589 Individuals.

Results

A total of six studies were included. Primary outcomes assessed were MRI-PDFF, AST, ALT, HOMA-IR and total bilirubin. Empagliflozin significantly reduced liver fat compared to placebo, with a pooled standardized mean difference (SMD) of −0.43 (95% CI: −0.82 to −0.04; p = 0.03; I² = 0%). AST also showed a significant reduction (SMD = −0.41; 95% CI: −0.66 to −0.16; p = 0.001; I² = 34%), while ALT showed a non-significant trend favoring empagliflozin (SMD = −0.60; 95% CI: −1.25 to 0.04; p = 0.07) with high heterogeneity (I² = 91%). No significant effects were observed for HOMA-IR (SMD = −0.10; 95% CI: −0.43 to 0.24; p = 0.57) or total bilirubin (SMD = −0.04; 95% CI: −1.16 to 1.08; p = 0.94). Among secondary outcomes, only liver segment VIII showed a significant benefit (SMD = −0.97; 95% CI: −1.68 to −0.25; p = 0.008), though heterogeneity remained substantial (I² = 79%). No significant changes were found in total cholesterol.

Conclusion

MRI-PDFF showed that empagliflozin significantly reduced liver fat and AST levels, indicating a beneficial effect on liver health in patients with type 2 diabetes and NAFLD.